ELDN ▲ +0.7% - Eledon Pharmaceuticals, Inc. $ELDN - Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 Eledon Pharmaceuticals rose 0.7% following news that the company submitted an Investigational New Drug application for islet cell transplantation, enrolled first patients across multiple transplant programs, and reaffirmed its timeline to begin a Phase 3 kidney transplantation trial in the fourth quarter of 2026. The announcements represent clinical progress on the company's transplantation pipeline and suggest the near-term catalysts remain on track. 03-SEP-2026 07:00 AM ET